# Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

> **NCT01755689** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1300 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal vaccine GSK134612
- **BIOLOGICAL:** Cervarix®
- **BIOLOGICAL:** Boostrix®

## Key facts

- **NCT ID:** NCT01755689
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-11
- **Primary completion:** 2014-04-29
- **Final completion:** 2014-04-29
- **Target enrollment:** 1300 (ACTUAL)
- **Last updated:** 2018-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755689, "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01755689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*